296 related articles for article (PubMed ID: 34308869)
1. Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR).
Ekici B; Yaman M; Küçük M; Dereli S; Yenerçağ M; Yiğit Z; Baş MM; Karavelioğlu Y; Çakmak HA; Kıvrak T; Özkan H; Altın C; Şabanoğlu C; Demirkan B; Ataş AE; Kılıçaslan F; Altay H; Tengiz İ; Fahri Erkan A; Kılıçaslan B; Olgun FE; Durakoğlugil ME; Alhan A; Zoghi M
Turk Kardiyol Dern Ars; 2021 Jul; 49(5):357-367. PubMed ID: 34308869
[TBL] [Abstract][Full Text] [Related]
2. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
Mazza A; Townsend DM; Torin G; Schiavon L; Camerotto A; Rigatelli G; Cuppini S; Minuz P; Rubello D
Biomed Pharmacother; 2020 Oct; 130():110596. PubMed ID: 34321170
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of angiotensin receptor neprilysin inhibitor therapy in heart failure patients with reduced ejection fraction: A retrospective cohort study.
Koçak A; Aydin S; Alibaşiç H; Çiçek M; Ekici B
Medicine (Baltimore); 2023 Oct; 102(43):e35589. PubMed ID: 37904474
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
Tsutsui H; Momomura S; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Guo W
J Cardiol; 2017 Sep; 70(3):225-231. PubMed ID: 28024961
[TBL] [Abstract][Full Text] [Related]
5. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
[TBL] [Abstract][Full Text] [Related]
6. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
[TBL] [Abstract][Full Text] [Related]
7. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD
JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619
[TBL] [Abstract][Full Text] [Related]
8. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
9. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
[TBL] [Abstract][Full Text] [Related]
10. Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure.
Sun Y; Song S; Zhang Y; Mo W; Zhang X; Wang N; Xia Y; Tse G; Liu Y
ESC Heart Fail; 2022 Feb; 9(1):667-675. PubMed ID: 34779134
[TBL] [Abstract][Full Text] [Related]
11. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
[TBL] [Abstract][Full Text] [Related]
12. Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis.
Rattanavipanon W; Sotananusak T; Yamaae F; Chandrsawang A; Kaewkan P; Nathisuwan S; Yingchoncharoen T
BMC Cardiovasc Disord; 2021 Jul; 21(1):324. PubMed ID: 34215190
[TBL] [Abstract][Full Text] [Related]
13. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
[TBL] [Abstract][Full Text] [Related]
14. ARNI in HFrEF-One-Centre Experience in the Era before the 2021 ESC HF Recommendations.
Niemiec R; Morawska I; Stec M; Kuczmik W; Swinarew AS; Stanula A; Mizia-Stec K
Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206278
[TBL] [Abstract][Full Text] [Related]
15. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
16. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
Solomon SD; Zile M; Pieske B; Voors A; Shah A; Kraigher-Krainer E; Shi V; Bransford T; Takeuchi M; Gong J; Lefkowitz M; Packer M; McMurray JJ;
Lancet; 2012 Oct; 380(9851):1387-95. PubMed ID: 22932717
[TBL] [Abstract][Full Text] [Related]
17. Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction.
Khariton Y; Fonarow GC; Arnold SV; Hellkamp A; Nassif ME; Sharma PP; Butler J; Thomas L; Duffy CI; DeVore AD; Albert NM; Patterson JH; Williams FB; McCague K; Spertus JA
JACC Heart Fail; 2019 Nov; 7(11):933-941. PubMed ID: 31521679
[TBL] [Abstract][Full Text] [Related]
18. Novel doses of sacubitril/valsartan in patients unable to tolerate traditional therapy: Effects on N-terminal pro B-type natriuretic peptide levels.
Pandey AC; Jer D; Kuo RS; Yoo DH; Christophy A; Mohan RC; Srivastava AV; Heywood JT
Clin Cardiol; 2021 Jan; 44(1):85-90. PubMed ID: 33277928
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
Hsiao FC; Wang CL; Chang PC; Lu YY; Huang CY; Chu PH
J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):152-157. PubMed ID: 31514513
[TBL] [Abstract][Full Text] [Related]
20. Effects of the Angiotensin-Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis.
Wang Y; Zhou R; Lu C; Chen Q; Xu T; Li D
J Am Heart Assoc; 2019 Jul; 8(13):e012272. PubMed ID: 31240976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
